Related Experiment Video
Updated: Mar 15, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
Antidepressant Medication Treatment and Risk of Death
Kara Zivin1, H Myra Kim, Matheos Yosef
1From the *Department of Veterans Affairs, Center for Clinical Management Research; †Department of Psychiatry, University of Michigan Medical School; ‡Department of Health Management and Policy, University of Michigan School of Public Health; §Institute for Social Research and ‖Center for Statistical Consultation and Research, University of Michigan; and ¶Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI; #VA Center for Healthcare Organization and Implementation Research, Department of Veterans Affairs, VA Medical Center, Bedford; and **Departments of Psychiatry and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA; and ††Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA.
Objective:
Although previous studies have assessed whether depression is a mortality risk factor, few have examined whether antidepressant medications (ADMs) influence mortality risk.
Methods:
We estimated hazards of 1-year all-cause mortality associated with ADMs, with use occurring within 90 days of depression diagnosis among 720 821 patients who received treatment in a Veterans Health Administration facility during fiscal year 2006. We addressed treatment selection biases using conventional Cox regression, propensity-stratified Cox regression (propensity score), and 2 forms of marginal structural models. Models accounted for multiple potential clinical and demographic confounders, and sensitivity analyses compared findings by antidepressant class.
Results:
Antidepressant medication use compared with no use was associated with significantly lower hazards of 1-year mortality risk in Cox (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.90-0.97) and propensity score estimates (HR, 0.94; 95% CI, 0.91-0.98), whereas marginal structural model-based estimates showed no difference in mortality risk when the exposure was specified as "as-treated" in every 90-day intervals of the 1-year follow-up (HR, 0.91; 95% CI, 0.66-1.26) but showed increased risk when specified as "intent-to-treat" (HR, 1.07; 95% CI, 1.02-1.13).
Conclusions:
Among patients treated with ADMs belonging to a single class in the first 90 days, there were no significant differences in 1-year all-cause mortality risks. When accounting for clinical and demographic characteristics and treatment selection bias, ADM use was associated with no excess harm.
More Related Videos
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Drug Therapy
Antianxiety Medications
Electroconvulsive Therapy
Mania and Antimanic Drugs: Overview

